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PAcquired von Willebrand Syndrome After
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Contributes to a High Prevalence of Bleeding During
Long-Term Support and at the Time of Transplantation
Nir Uriel, MD,* Sang-Woo Pak, MD,† Ulrich P. Jorde, MD,* Brigitte Jude, MD, PHD,‡
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Objectives The objective of the study was to determine the prevalence of bleeding during continuous-flow left ventricular
assist device support and to identify potential mechanisms for those bleeding events.
Background Bleeding is frequently reported with continuous-flow left ventricular assist devices and may result from anticoag-
ulation coupled with bleeding diathesis such as acquired von Willebrand syndrome. Accordingly, the prevalence
of coagulation abnormalities including laboratory assessment for von Willebrand syndrome, bleeding events dur-
ing device support, and at heart transplantation were evaluated.
Methods A retrospective study in all HeartMate II (HM II) (Thoratec Corp., Pleasanton, California) patients who underwent im-
plantation between April 1, 2004, and August 1, 2009, was performed. Bleeding was defined as the need for transfu-
sion 7 days after device insertion of 1 U of packed red blood cells. Transfusion at heart transplantation was com-
pared with that in HeartMate XVE patients.
Results Seventy-nine HM II devices were implanted. Anticoagulation included warfarin in 68.3%, aspirin in 55.7%, and
dipyridamole in 58.2% of the patients. Of the patients, 44.3% had bleeding episodes at 112  183 days after
left ventricular assist device implantation, with 50% experiencing an event within 2 months. Gastrointestinal
bleeding was the most frequent event. At the index event, the international normalized ratio averaged 1.67 
0.53, and the platelet count was 237  119  109/l. Comparison of the transfusion requirements at heart
transplantation of 35 HM II patients with 62 HeartMate XVE patients demonstrated twice the transfusion re-
quirements in HM II patients (packed red blood cells, 6.3  0.8 U vs. 3.8  0.5 U; platelets, 12.5  5.4 U vs.
8.6  6.4 U; fresh frozen plasma, 9.6  4.9 U vs. 4.9  3.6 U; and cryoprecipitate, 4.3  3.6 U vs. 2.2  3.5 U;
p  0.05 for all). High molecular weight von Willebrand factor multimers were measured in 31 HM II patients
and were reduced in all patients; 18 of these 31 (58%) patients had bleeding.
Conclusions Patients with the HM II had a high incidence of bleeding events during device support and at heart transplanta-
tion. All HM II patients had reduced high molecular weight von Willebrand factor multimers. The role of these
abnormalities in the high incidence of bleeding deserves further investigation. Furthermore, alterations in anti-
coagulation should be considered during device support and before surgery in patients supported with the
HM II. (J Am Coll Cardiol 2010;56:1207–13) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.05.016e
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ccepted May 25, 2010.ither a bridge to transplantation or an alternative to
ransplantation (i.e., destination therapy [DT]). The limited
urability and thrombotic complications of the first-
See page 1214
eneration mechanical support devices precluded wide-
pread application. Newer generation mechanical devices
sing axial continuous-flow pumps have been increasingly
sed as a bridge to transplantation. Axial flow pump design
ncludes a single moving part, the rotor, suspended by
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High Rate of Bleeding With Continuous-Flow Devices October 5, 2010:1207–13bearings that quietly spin at
8,800 to 10,000 rpm. The re-
duced size, increased durability,
ease of implantation, and re-
duced infections associated with
these pumps are some of the
advantages of these new devices.
Clinical trials using these newer
pump designs have demonstrated
efficacy in providing hemody-
namic support and a favorable
risk-to-benefit ratio in both bridge
to transplantation (1) and DT (2)
populations. However, thrombo-
embolic events are still frequent
adverse events with these devices,
which require the use of long-term
anticoagulation therapy with both
warfarin and antiplatelet drugs.
Bleeding complications associated
with these devices range from as
ow as 17.5% (3) to as high as 63 events/100 patient-years
4). Owing to the need for anticoagulation, a greater
revalence of bleeding is anticipated with continuous-flow
evices such as the HeartMate II (HM II) (Thoratec Corp.,
leasanton, California) than with the pulsatile devices such
s the HeartMate XVE (HM XVE) (Thoratec Corp.).
hether this bleeding tendency is simply a consequence of
nticoagulation therapy has recently been challenged by
eports that suggest that the device design affects hemostatic
actors and results in acquired von Willebrand (VW) syn-
rome (5–7).
Accordingly, we reviewed our experience with a commonly
sed axial flow pump, the HM II, to better define the
revalence of bleeding in these patients and the need for
ransfusion during subsequent surgeries, notably heart trans-
lantation (HT). In those patients with bleeding complica-
ions, hemostasis studies were performed to determine whether
cquired WV syndrome developed in these patients.
ethods
retrospective chart review was performed from April 1,
004, to August 1, 2009, of all continuous-flow device
atients who underwent implantation at a single large
edical center. Minor bleeding was defined as observable
lood loss without the need for transfusion. Major bleeding
as defined as need for blood transfusion 7 days after
evice insertion. Hemorrhagic events analyzed included
emorrhagic stroke and bleeding requiring at least 1 U of
acked red blood cells. Blood transfusion for hemolysis (n 1)
as excluded from the bleeding analysis. Thrombotic events
nalyzed included ischemic stroke, pump thrombosis, and
ystemic embolic events. Stroke was defined as any neuro-
ogic event lasting 24 h and categorized as having a
Abbreviations
and Acronyms
DT  destination therapy
HM II  HeartMate II
HMW  high molecular
weight
HM XVE  HeartMate XVE
HT  heart transplantation
INR  international
normalized ratio
LVAD  left ventricular
assist device
vW  von Willebrand
vWF  von Willebrand
factor
vWF:Ag  von Willebrand
factor antigen
vWF:Rco  von Willebrand
ristocetin cofactoremorrhagic or thromboembolic etiology according to the Oesults of intracranial imaging. Pump thrombosis was de-
ned as any thrombus within the device or its conduits
ssociated with clinical signs of impaired pump perfor-
ance.
Blood product requirements during HT were collected
nd compared in patients bridged with HM II with patients
ridged with HM XVE.
Platelet counts, prothrombin time, partial thromboplastin
ime, international normalized ratio (INR) were obtained in
ll patients. von Willebrand factor (vWF) antigen (VWF:
g), vWF ristocetin cofactor activity (VWF:Rco), and vWF
ultimeric structure were measured in patients with major
leeding events or before HT and in a random group of
atients with heart failure before HM II support or during
upport with other devices. vWF:Ag was measured using an
mmunoturbidiumetric assay, and vWF:Rco was measured
sing platelet aggregometer PAP4. The multimeric struc-
ure analysis was performed as described by Daniels et al.
8), and represents a qualitative measurement of the pres-
nce or absence of the largest vWF multimers (high
olecular weight [HMW]). Acquired vW syndrome was
efined as the decrease in or absence of the largest vW
ultimers (HMW). Serial testing was obtained in those
atients who underwent HT.
tatistical analysis. Data were collected using Excel Soft-
are (2007 Microsoft Corp., Redmond, Washington). All
ata were analyzed using the Stata version 11.0 (StataCorp.,
ollege Station, Texas). Categorical variables were summa-
ized by frequencies and percentages, and were analyzed
sing chi-square test. Student t test for independent samples
as used to determine differences in normally distributed
ata. The Wilcoxon rank sum test was used to determine
ifferences in non-normal distributions.
esults
revalence of bleeding in continuous-flow mechanical
ssist devices. Seventy-nine patients (mean age 56  14
ears) had an HM II implanted with 64 patients receiving
he device as bridge to transplantation and 15 patients
eceiving it as DT. The patient population is described in
able 1. During a follow-up period of 370  486 days
range 3 to 1,978 days), 40 patients underwent HT; 15
atients died.
During LVAD support, 44 patients had no significant
leeding episodes (Normal) and 35 patients (44.3%) had
ajor bleeding episodes (Bleed). The mean time to bleeding
rom LVAD implantation was 112  183 days with 50% of
pisodes occurring within 2 months (median 56 days).
The most common bleeding event was gastrointestinal;
4 patients had gastrointestinal bleeding, 21 patients un-
erwent at least 1 endoscopy, whereas 5 patients had
ultiple endoscopies. Chest bleeding requiring a surgical
rocedure was reported in 7 patients (pericardial effusion/
amponade in 6 patients and pleural effusion in 1 patient).
ther bleeding sources included oral (after dental extrac-
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October 5, 2010:1207–13 High Rate of Bleeding With Continuous-Flow Devicesion, n  1), muscle (n  1), epistaxis (n  1), and
ost-menopausal bleeding (4 episodes). Epistaxis was re-
orted in 7 patients, but only 1 patient required blood
ransfusion. Transfusion requirements averaged 5.7 U of
acked red blood cells per bleeding patient (range 2 to
40 U) (Table 2).
Major bleeding events were observed more frequently in
lder patients (Fig. 1) (60.1  13.5 years vs. 53.4  13.2
ears, p 0.03) and those with ischemic cardiomyopathy as
heir underlying heart failure etiology (58.8% vs. 33.3%, p
.03) Hypertension was also more common (61.8% vs.
6.4%, p  0.026).
Anticoagulant use at the time of a bleeding event was not
tatistically different between the groups (Table 3). The
NR averaged 1.67  0.53 with an INR 2.5 noted only in
patients. The platelet count was 237  119  109/l, with
low platelet count in 1 patient (48  109/l). Five patients
xperienced thromboembolic events: 2 had cerebrovascular
ccidents in the middle cerebral artery territory, 1 had a
opliteal artery embolism, and 2 embolic events were noted
fter treatment with intravenous immunoglobulin (1 sys-
emic event with a fatal outcome and 1 aortic valve throm-
us event). The mean time to thromboembolic events after
VAD implantation was 126  134 days, whereas 50%
xperienced the event within 2 months (median 30 days).
omparison of blood transfusion requirements during
T in patients bridged with continuous-flow devices
ersus pulsatile flow devices. Thirty-five patients (age
3  2 years, 84.2% men) with an HM II underwent HT.
M II Patient Characteristics (n  79)Table 1 HM II Patient Characteristics (n  79)
Age (yrs) 56.3 13.7
Male sex, n (%) 63 (79.8)
Body mass index (kg/m2) 25.9 5.0
BTT/DT 63/14
Heart failure etiology, n (%)
ICM 33 (45.2)
DCM 40 (54.8)
Previous thoracic surgery, n (%) 22 (29.0)
Diabetes, n (%) 26 (33.3)
Hypertension, n (%) 37 (47.4)
Left ventricular ejection fraction 16.1 7.2
Obstructive lung disease, n (%) 6 (7.7)
Lietz score (n  63) 9.1
TT  bridge to transplantation; DCM  dilated cardiomyopathy; DT  destination therapy;
M II  HeartMate II; ICM  ischemic cardiomyopathy.
leeding Events Requiring TransfusionTable 2 Bleeding Events Requiring Transfusion
Event Site n Event
GI 24
Chest 7 6 pericardial effusion, 1 hemothorax
Other 3 Dental, LE wound, postmenopausal
Epistaxis 1
Total 35I  gastrointestinal; LE  lower extremity.
B
fheir blood product requirements during surgery were
ompared with those of 62 patients (age 53  2 years,
0.6% men) with an HM XVE who underwent HT during
he same time period. More HM II patients were treated
ith warfarin (89.5% vs. 31.2%, p  0.001), aspirin (76.3%
s. 59.0%, p 0.078), and dipyridamole (63.2% vs. 0%, p
.001). Patients supported with an HM II required twice
he amount of blood products during HT compared with
atients supported with an HM XVE (Table 4). Comparing
M II patients with a subgroup of HM XVE patients who
lso received warfarin treatment revealed the same differ-
nces in transfusion requirements after HT.
Figure 1 Bleeding Frequency per Quartile Age Group
Major bleeding events occurred more frequently in older patients, with patients
older than age 66 years having twice the risk of bleeding during device support
compared with patients younger than 44 years of age. Age groups: 18 to 44
years, n  20; 45 to 59 years, n  19; 60 to 66 years, n  19; 66 years
(n  20); p  0.027.
omparison of Clinical Characteristics ofatients Wh Did and Did Not BleedTable 3 Comp rison of Clinical Characteristics ofPatients Who Did and Did Not Bleed
Characteristic Bleed Normal p Value
Age (yrs) 60.1 13.5 53.4 13.2 0.031
Male sex, n (%) 30 (85.7) 33 (75) 0.239
Basic metabolic index 26.3 5.4 25.3 4.5 0.398
Ejection fraction (%) 16.1 6.0 16.1 8.3 0.998
BTT, n (%) 26/8 (76.5) 37/6 (86.1) 0.279
HF etiology, n (%)
ICM 20 (58.8) 13 (33.3) 0.029
DCM 14 (41.2) 26 (66.7)
Diabetes 12 (35.3) 14 (31.8) 0.747
Hypertension 21 (61.8) 16 (46.4) 0.026
COPD 3 (8.8) 3 (6.8) 1
Lietz score 9.28 4.8 8.97 5.8 0.822
Anticoagulation, n (%)
Warfarin 24 (75.0) 30 (79.0) 0.695
Aspirin 19 (59.4) 25 (65.8) 0.58
Dipyridamole 20 (62.5) 26 (68.4) 0.603TT  bridge to transplantation; COPD  chronic obstructive pulmonary disease; HF  heart
ailure; other abbreviations as in Table 1.
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High Rate of Bleeding With Continuous-Flow Devices October 5, 2010:1207–13ossible mechanism: acquired VW syndrome and
ontinuous-flow assist devices. Thirty-one patients (27
en) with HM II support were evaluated for vW
yndrome; 18 patients were tested after major bleeding
vents and 13 were tested before anticipated surgeries.
ll patients had decreased or absent HMW forms of
WF needed for platelet adhesion, which is sufficient for
he diagnosis of acquired vW syndrome. vWF:Ag was
04  107%, and vWF:Rco was 102  27%, both within
ormal range. When the levels of vWF:Ag and vWF:Rco
ere divided by the median level and the incidence of
leeding in those groups were compared, no significant
ifferences in bleeding events were noted (p  0.45 and
 0.275, respectively).
All patients tested with bleeding events had vW syn-
rome with decreased to absent HMW vW multimers.
ixteen patients had gastrointestinal bleeding, and 2 pa-
ients had pericardial bleeding.
In all 6 patients who had vWF levels measured during HM
I support and repeated after HT, there was normalization of
he HMW vWF multimer levels with a statistically significant
levation in vWF:Ag and vWF:Rco (Table 5). In 1 patient,
ormal HMW vWF multimer levels pre-implantation de-
reased with HM II support.
Additionally, vWF levels were measured in a variety of
dvanced heart failure conditions in random fashion. Three
atients with advanced heart failure on inotropic support
ad normal HMW vWF multimer levels. Two patients
ith an HM XVE and 1 patient with a Duraheart (Terumo
eart Inc., Ann Arbor, Michigan) had normal HMW vWF
ultimer levels. One patient with CentriMag BiVad (Tho-
atec Corp.) support as a bridge to transplantation had
ecreased HMW vWF multimers. None of the patients
ith normal vWF multimer levels had a bleeding event (18
f 31 vs. 0 of 6, p  0.001).
ransfusion Requirementsuring Heart TransplantationTable 4 Transfusio RequirementsDuring Heart Transplantation
HM XVE (n  62) HM II (n  35) p Value
Packed red blood cells (U) 3.8 0.5 6.3 0.8 0.0055
Platelets (U) 8.6 6.4 12.5 5.4 0.0027
Fresh frozen plasma (U) 4.9 3.6 9.6 4.9 0.0000
Cryoprecipitate (U) 2.2 3.5 4.3 3.6 0.0035
CellSaver (U) 3.9 2.3 5.0 4.0 0.50
M  HeartMate.
von Willebrand Factor Levels (n  31)Table 5 von Willebrand Factor Levels (n  3
During VA
Decreased or absent VW multimers 100
VW antigen 203.5 107.1,
Ristocetin 102.4 26.6, mVAD  ventricular-assist device; VW  von Willebrand.iscussion
e examined the prevalence of major bleeding episodes in
dvanced heart failure patients supported with a continuous-
ow LVAD (HM II). vWF levels were studied during the
upport time, and blood product requirements were collected
n those patients who underwent HT. Thirty-five patients
44.3%) had major bleeding episodes at a median time of 56
ays after device implantation; gastrointestinal bleeding was
he most common source. At HT, HM II patients required
ignificantly higher amounts of blood products compared with
M XVE patients, even a subgroup receiving warfarin. Ac-
uired vW syndrome developed in all patients on device
upport diagnosed by the decrease in or absence of HMW
WF multimers. This hemostatic abnormality may explain the
xcessive bleeding in the continuous-flow device patients.
In recent years, LVADs using rotary pump technology to
rovide continuous flow with reduced pulsatility have
hown great promise (1,2). These continuous-flow LVADs
mprove hemodynamics, end-organ function, quality of life,
nd functional capacity of patients awaiting HT (1,9).
ecently, Slaughter et al. (2) reported that implantation of
continuous-flow LVAD, compared with a pulsatile-flow
evice, significantly improved survival at 2 years in patients
ith advanced heart failure who were ineligible for HT.
ased on these and other clinical data, many centers have
ransitioned from pulsatile-flow devices to continuous-flow
evices. With the recent approval of the HM II by the U.S.
ood and Drug Administration as DT, an increase in
VAD implantation among patients who are ineligible for
T is anticipated.
Patients with continuous-flow devices require anticoagu-
ation and antiplatelet agents to attenuate the risk of
hromboembolic events. Results from the HM II Pivotal
rial supported the use of aspirin at a dose of 81 mg/day and
arfarin achieving and maintaining an INR of 2.0 to 3.0 as
oon as post-operative bleeding was controlled. Case series
ave suggested that gastrointestinal bleeding may be a more
requent complication with continuous-flow devices (10).
row et al. (4) reported in a series of 101 patients that the
ate of gastrointestinal bleeding was significantly higher in
atients receiving continuous-flow LVADs compared with
ulsatile devices. There were 63 gastrointestinal bleeding
vents per 100 patient-years in nonpulsatile device recipi-
nts compared with 6.8 in the pulsatile group (p  0.0004).
ossible pathophysiological explanations for these phenom-
na included the increased use of anticoagulation and/or the
evelopment of a bleeding diathesis.
After HT p Value
0% 0.001
n 187 309.5 83.0, median 327 0.03
117 144.0 53.7, median 120 0.0091)
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October 5, 2010:1207–13 High Rate of Bleeding With Continuous-Flow DevicesMultiple studies have been done using warfarin in chronic
eart failure patients. In the HELAS (Heart Failure Long
erm Antithrombotic Study), 197 chronic heart failure
atients were randomized to treatment with aspirin or
arfarin. Major hemorrhage occurred in the warfarin group
t a rate of 0.046 per patient-year and was to the result of
veranticoagulation. Similar results were reported in the
ASH (Warfarin/Aspirin Study in Heart Failure) (11,12).
he WATCH (Warfarin and Antiplatelet Therapy in
eart Failure Trial) (13) examined the role of anticoagula-
ion in 1,587 chronic heart failure patients and compared
arfarin, aspirin, and clopidogrel. Although increased
leeding was reported in the warfarin group (5.2% vs. 3.6%
s. 2.1%, respectively), this bleeding rate is significantly
ower than the event rate observed in our series. In the
ontext of these studies, our findings suggest that the high
leeding rate seen in our cohort cannot be totally attributed
o anticoagulation therapy.
In 1958, Heyde et al. (14) reported a high incidence of
astrointestinal bleeding in aortic stenosis patients (Heyde
yndrome). In the 1990s, Warkentin et al. (15) raised the
uestion of whether stenotic aortic valves predisposed pa-
ients to the development of acquired vW syndrome, which
ould contribute to high bleeding events from gastrointes-
inal angiodysplasia, which is common in these patients.
urther studies by several investigators have shown that
ortic stenosis and gastrointestinal bleeding are associated
ith acquired type 2A vW syndrome, which is characterized
y the loss of HMW vWF multimers (15,16). High shear
orces induce structural changes in the shape of the vWF
olecule, leading to exposure of the bond between amino
cids 842 and 843. This results in proteolysis of the highest
olecular weight multimers of vWF, which are the most
ffective in platelet-mediated hemostasis under conditions
f high shear stress (17,18). Aortic valve replacement
everses this hematological syndrome (19,20). Continuous-
ow LVADs may cause a similar syndrome. Geisen et al. (7)
eported an impaired function of vWF with respect to
inding to collagen and to platelet receptor GPIb (reflected
y ristocetin cofactor activity) and loss of HMW biologi-
ally active vWF multimers in 7 HM II patients. In our
tudy, all HM II patients who underwent vWF testing had
ow to absent levels of HMW vWF multimers. HT reversed
his phenomenon, suggesting that the LVAD support was
ausative of acquired VW syndrome. The vWF level
hanges in our cohort are especially noteworthy, given the
tudy by Lip et al. (21) that demonstrated a positive
orrelation between heart failure and increased plasma vWF
oncentrations, with highest plasma vWF levels in patients
ith acute or recent decompensated chronic heart failure.
In a recent study of HM II patients by Boyle et al. (3), the
ate of thromboembolic events (3%) was not dissimilar from
ur findings (6.3%). Anticoagulation is indicated but given
he development of acquired vW syndrome in continuous-
ow LVAD patients, the current guidelines recommending
he use of warfarin in conjunction with antiplatelet agents teeds to be reconsidered. The role of routine follow-up of
WF levels and the adjustment of antiplatelets and/or the
NR levels to the degree of acquired vW syndrome severity
hould be studied. Although this study focused on the HM
I, this phenomenon may be occurring with other
ontinuous-flow devices. vWF abnormalities were also de-
cribed in BiVad devices (7) and centrifugal pumps (6), and
he clinical implication of those findings may be similar:
ncreased major bleeding events and need for more blood
roducts during HT.
The effects of this bleeding diathesis may change the
ourse of the HT in patients bridged with HM II. During
T surgery, patients with HM II received double the
mount of blood products than did patients bridged with
he HM XVE. Kuduvalli et al. (22) reported that periop-
rative red blood cell transfusion after cardiac procedures
as associated with an increased risk of death during a
-year follow-up. In general, transfusions of blood products
re associated with increased risk of short- and long-term
omplications. Minor transfusion reactions, such as fever
nd hypotension, occur frequently. Major transfusion reac-
ion such as transfusion-related acute lung injury and a
ulmonary leukoagglutinin reaction are less common (23).
n our population, transfusion-related acute lung injury
ight have been masked because clinical signs can be
onfounded by post-operative complications such as atelec-
asia, congestive heart failure, and pleural fluid or as a
onsequence of ischemia and reperfusion injury induced by
ardiopulmonary bypass (24). Other complications may
esult from substantial changes in the immune system after
ransfusion. Banbury et al. (25) reported that the risk
f infection increased incrementally with each unit of
lood transfused in 15,592 post-cardiac surgery patients.
hose infections can include bacteria/viral (e.g., human
mmunodeficiency virus, hepatitis B virus, hepatitis C vi-
us) and transmissible spongiform encephalopathies (e.g.,
reutzfeldt-Jacob disease) (26). Whether the increase in
lood product transfusions observed in our series carries an
ncreased risk of the complications mentioned needs to be
nvestigated.
The effect of LVAD on post-transplantation mortality
as a subject for many studies and yielded conflicting
esults. Recently, Patlolla et al. (27) conducted a retrospec-
ive analysis in 11,336 patients entered into the United
etwork for Organ Sharing Thoracic Registry to examine
he relationship between intracorporeal and extracorporeal
AD implantation and post-transplantation mortality.
hey reported that intracorporeal ventricular assist devices
re associated with a small increase in mortality in the first
months and a clinically significant increase in mortality
eyond 5 years. The increased use of blood products that we
re reporting here may be an explanation for this report, by
ncreasing allosensitization during LVAD support. In con-
rast, Pal et al. (28) compared the transplantation outcomes
f patients bridged with an LVAD and intravenous ino-
ropes. They reported no increase in post-transplantation
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High Rate of Bleeding With Continuous-Flow Devices October 5, 2010:1207–13orbidity or mortality and did not observe an increased
ncidence of rejection episodes in the first year after HT.
urthermore, measured levels of anti–human leukocyte
ntigen antibodies were similar in the LVAD group com-
ared with the intravenous inotrope group. Our group’s
nalysis of the United Network for Organ Sharing data
or adult heart transplant recipients from January 1, 2001,
o December 31, 2006, found that the use of intracorpo-
eal and paracorporeal devices was not associated with
ecreased survival after HT (29) and concurs with the
eport of Pal et al. (28).
tudy limitations. This is a single-center study of a small
umber of patients who were screened for vW syndrome if
leeding was present or if surgery was anticipated. There-
ore, all device-supported patients were not screened. The
ncidence and the timing of the development of this
yndrome cannot be derived from this study.
onclusions
atients supported by an HM II have a high risk of major
leeding during the support time and at the time of HT.
he increased prevalence of bleeding with continuous-flow
evices is not explained by excessive anticoagulation ther-
py. Acquired vW syndrome occurs almost uniformly in
atients on continuous-flow assist devices and appears to be
significant contributor to the observed bleeding. Bleeding
uring HM II support is particularly frequent in older
atients and, unless prevented, may constitute a major
imitation of DT. Routine monitoring of vWF multimers or
f their activity and alteration of anticoagulation treatment
n these patients should be addressed.
Given our current observations, our program has de-
eloped the following approach to bleeding complications
n patients with continuous-flow devices. All anticoagu-
ation medications are discontinued during the bleeding
pisode and until hemodynamic stability is achieved. The
leeding site is identified and corrected, if possible. After
tabilization of hemoglobin levels, anticoagulation treat-
ent is resumed on an individual patient basis consider-
ng the extent of bleeding, the patient’s age, and the risk
f thrombosis. The majority of patients are restarted on
arfarin or aspirin alone. Although we can hypothesize
hat platelet inhibitors should be discontinued once a
ecrease in HMW vWF multimers is observed, we do not
ave enough data to recommend anticoagulation changes
ccording to vWF studies. A randomized, multicenter,
rospective trial is needed to define the optimal antico-
gulation regimen for patients supported with
ontinuous-flow devices.
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